RPL22 and myelodysplastic syndrome: Approximately 40% of patients with MDS and 27% of patients with AML showed evidence of increased RPL22 deletion, with more of these patients being represented in the high-risk MDS and secondary AML groups (Figure 1J).28 Collectively, these data indicate that RPL22 expression is frequently reduced in patients with MDS/AML, including in their HSPCs, and that low RPL22 expression is associated with reduced survival and thus more aggressive myeloid disease.